Cecile D Lahiri1,2, Minh Ly Nguyen1,2, C Christina Mehta2,3, Marina Mosunjac4, Talaat Tadros4, Elizabeth R Unger5, Mangalathu S Rajeevan5, Jendai Richards5, Ighovwerha Ofotokun1,2, Lisa Flowers2,6. 1. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Georgia. 2. Atlanta Women's Interagency HIV Study, Rollins School of Public Health, Emory University, Georgia. 3. Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Georgia. 4. Department of Pathology, Emory University School of Medicine, Georgia. 5. Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Georgia. 6. Department of Gynecology and Obstetrics, Emory University School of Medicine, Georgia.
Abstract
BACKGROUND: Anal cancer rates have increased, particularly in human immunodeficiency virus (HIV)-infected (HIV+) women. We assessed factors associated with anal precancer in HIV+ and at-risk HIV-negative women from the Atlanta Women's Interagency HIV Study cohort. METHODS: All participants underwent high-resolution anoscopy and anal cytology and had anal and cervical samples collected. Specimens were tested for 37 human papillomavirus (HPV) types and for FAM19A4 and microRNA124-2 promoter methylation. Binary logistic regression and multivariate analysis were conducted with histologic anal high-grade squamous intraepithelial lesion (A-HSIL) as the dependent variable. RESULTS: Seventy-five women were enrolled: 52 (69%) were HIV+ with three-fourths having undetectable viral load; 64 (86%) were black; mean age was 49 ± 8 years. Forty-nine (65%) anal cytology samples were abnormal, and 38 (51%) of anal samples were positive for at least 1 of 13 high-risk HPV (hrHPV) types. Thirteen (18%) anal biopsies identified A-HSIL. Hypermethylation of FAM19A4 and/or microRNA124-2 was found in 69 (95%) anal samples and 19 (26%) cervical samples. In multivariate analyses, the odds of having A-HSIL were >6 times higher in women with anal hrHPV (adjusted odds ratio [aOR], 6.08 [95% confidence interval {CI}, 1.27-29.18], P = .02) and with positive cervical methylation (aOR, 6.49 [95% CI, 1.66-25.35], P = .007), but not significantly higher in women with positive anal methylation. CONCLUSIONS: Anal hrHPV and promoter hypermethylation in the cervix show promise as biomarkers for anal cancer screening in HIV+ and at-risk HIV-negative women. Greater understanding of gene silencing by promoter hypermethylation in anal carcinogenesis is needed.
BACKGROUND:Anal cancer rates have increased, particularly in human immunodeficiency virus (HIV)-infected (HIV+) women. We assessed factors associated with anal precancer in HIV+ and at-risk HIV-negative women from the Atlanta Women's Interagency HIV Study cohort. METHODS: All participants underwent high-resolution anoscopy and anal cytology and had anal and cervical samples collected. Specimens were tested for 37 human papillomavirus (HPV) types and for FAM19A4 and microRNA124-2 promoter methylation. Binary logistic regression and multivariate analysis were conducted with histologic anal high-grade squamous intraepithelial lesion (A-HSIL) as the dependent variable. RESULTS: Seventy-five women were enrolled: 52 (69%) were HIV+ with three-fourths having undetectable viral load; 64 (86%) were black; mean age was 49 ± 8 years. Forty-nine (65%) anal cytology samples were abnormal, and 38 (51%) of anal samples were positive for at least 1 of 13 high-risk HPV (hrHPV) types. Thirteen (18%) anal biopsies identified A-HSIL. Hypermethylation of FAM19A4 and/or microRNA124-2 was found in 69 (95%) anal samples and 19 (26%) cervical samples. In multivariate analyses, the odds of having A-HSIL were >6 times higher in women with anal hrHPV (adjusted odds ratio [aOR], 6.08 [95% confidence interval {CI}, 1.27-29.18], P = .02) and with positive cervical methylation (aOR, 6.49 [95% CI, 1.66-25.35], P = .007), but not significantly higher in women with positive anal methylation. CONCLUSIONS: Anal hrHPV and promoter hypermethylation in the cervix show promise as biomarkers for anal cancer screening in HIV+ and at-risk HIV-negative women. Greater understanding of gene silencing by promoter hypermethylation in anal carcinogenesis is needed.
Authors: Susan S Reif; Kathryn Whetten; Elena R Wilson; Carolyn McAllaster; Brian W Pence; Sara Legrand; Wenfeng Gong Journal: AIDS Care Date: 2013-08-14
Authors: Denise J Jamieson; Ann Duerr; Robert Burk; Robert S Klein; Pangaja Paramsothy; Paula Schuman; Susan Cu-Uvin; Keerti Shah Journal: Am J Obstet Gynecol Date: 2002-01 Impact factor: 8.661
Authors: Elizabeth A Stier; Meagan C Sebring; Audrey E Mendez; Fatimata S Ba; Debra D Trimble; Elizabeth Y Chiao Journal: Am J Obstet Gynecol Date: 2015-03-19 Impact factor: 8.661
Authors: M Frisch; C Fenger; A J van den Brule; P Sørensen; C J Meijer; J M Walboomers; H O Adami; M Melbye; B Glimelius Journal: Cancer Res Date: 1999-02-01 Impact factor: 12.701
Authors: Erin M Siegel; Steven Eschrich; Kathryn Winter; Bridget Riggs; Anders Berglund; Abidemi Ajidahun; Jeff Simko; Jennifer Moughan; Jaffer Ajani; Anthony Magliocco; Abul Elahi; Sarah Hoffe; David Shibata Journal: Dis Colon Rectum Date: 2014-08 Impact factor: 4.585
Authors: Samuel Phillips; Kahli Cassells; Suzanne M Garland; Dorothy A Machalek; Jennifer M Roberts; David J Templeton; Fengyi Jin; I Mary Poynten; Richard J Hillman; Andrew E Grulich; Gerald L Murray; Sepehr N Tabrizi; Monica Molano; Alyssa M Cornall Journal: Sci Rep Date: 2022-03-03 Impact factor: 4.996
Authors: Ramon P van der Zee; Olivier Richel; Carel J M van Noesel; Iuliana Ciocănea-Teodorescu; Annina P van Splunter; Timo J Ter Braak; Mayura Nathan; Tamzin Cuming; Michael Sheaff; Alexander Kreuter; Chris J L M Meijer; Wim G V Quint; Henry J C de Vries; Jan M Prins; Renske D M Steenbergen Journal: Clin Infect Dis Date: 2021-06-15 Impact factor: 9.079